Swiss giant Roche secured exclusive worldwide rights to Antisoma’s pipeline of oncology products including Pemtumomab for treating ovarian and gastric cancer, Therex, TheraFab and DMXAA. Roche will also responsible for the late-stage development and commercialization of Antisoma’s oncology products.